Fintel reports that on December 17, 2025, JP Morgan upgraded their outlook for Recursion Pharmaceuticals (NasdaqGS:RXRX) from Neutral to Overweight.
Analyst Price Forecast Suggests 37.89% Upside
As of December 6, 2025, the average one-year price target for Recursion Pharmaceuticals is $6.46/share. The forecasts range from a low of $3.03 to a high of $10.50. The average price target represents an increase of 37.89% from its latest reported closing price of $4.68 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Recursion Pharmaceuticals is 88MM, an increase of 100.46%. The projected annual non-GAAP EPS is -1.41.
What is the Fund Sentiment?
There are 505 funds or institutions reporting positions in Recursion Pharmaceuticals. This is an decrease of 22 owner(s) or 4.17% in the last quarter. Average portfolio weight of all funds dedicated to RXRX is 0.18%, an increase of 0.59%. Total shares owned by institutions increased in the last three months by 4.20% to 378,294K shares. 
The put/call ratio of RXRX is 0.24, indicating a bullish outlook.
What are Other Shareholders Doing?
ARK Investment Management holds 33,545K shares representing 6.52% ownership of the company. In its prior filing, the firm reported owning 32,989K shares , representing an increase of 1.66%. The firm decreased its portfolio allocation in RXRX by 20.38% over the last quarter.
Baillie Gifford holds 23,979K shares representing 4.66% ownership of the company. In its prior filing, the firm reported owning 24,174K shares , representing a decrease of 0.81%. The firm decreased its portfolio allocation in RXRX by 5.12% over the last quarter.
ARKK - ARK Innovation ETF holds 19,950K shares representing 3.88% ownership of the company. In its prior filing, the firm reported owning 18,652K shares , representing an increase of 6.50%. The firm decreased its portfolio allocation in RXRX by 27.92% over the last quarter.
Softbank Group holds 14,667K shares representing 2.85% ownership of the company. No change in the last quarter.
Kinnevik AB holds 13,434K shares representing 2.61% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
